1832 Asset Management
HRMY icon

1832 Asset Management’s Harmony Biosciences HRMY Stock Holding History

1832 Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-115,800
Closed -$6.38M – 925
2022
Q4 		$6.38M Buy
+115,800
New +$6.37M 0.01% 400

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

1832 Asset Management's HRMY Position: Q1 2023 in Review

1832 Asset Management sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 115,800 shares — an estimated $6.38M sold.

1832 Asset Management first reported a position in HRMY in Q4 2022 and held it in 1 quarter. The position peaked at $6.38M in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

  • 1832 Asset Management reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
  • 1832 Asset Management sold 115,800 Harmony Biosciences shares in Q1 2023, an estimated $6.38M.
  • 1832 Asset Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 1 quarter.
  • 1832 Asset Management's Harmony Biosciences position peaked at $6.38M in Q4 2022.
  • 217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on 1832 Asset Management's 13F filing for Q1 2023, filed 12 May 2023.